PO-484 Development of a Two-Step Screening-And-Confirmation Approach to Efficiently Identify Synergistic Drug Combinations With the Parp Inhibitor Niraparib

doi 10.1136/esmoopen-2018-eacr25.503
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd

Related search

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

A Computational Approach for Identifying Synergistic Drug Combinations

PLoS Computational Biology
Molecular NeuroscienceEvolutionEcologyGeneticsBehaviorMolecular BiologySystematicsSimulationCellularComputational TheoryMathematicsModeling
2017English

Network Target for Screening Synergistic Drug Combinations With Application to Traditional Chinese Medicine

BMC Systems Biology
Molecular BiologyApplied MathematicsStructural BiologySimulationComputer Science ApplicationsModeling
2011English

Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors With Three Different Drug Combinations

PLoS ONE
Multidisciplinary
2016English

In Vivo Anti-Tumor Activity of the PARP Inhibitor Niraparib in Homologous Recombination Deficient and Proficient Ovarian Carcinoma

Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Developing Synergistic Drug Combinations to Restore Antibiotic Sensitivity in Drug-Resistant Mycobacterium Tuberculosis

2019English

Nanomedicine of Synergistic Drug Combinations for Cancer Therapy – Strategies and Perspectives

Journal of Controlled Release
Pharmaceutical Science
2016English

Screening Strategies to Identify New Chemical Diversity for Drug Development to Treat Kinetoplastid Infections – CORRIGENDUM

Parasitology
Animal ScienceZoologyParasitologyInfectious Diseases
2013English

Barrier to Resistance of Dolutegravir in Two-Drug Combinations

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy